Home > Oncology > ESMO 2021 > Gastrointestinal Cancer > Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By
Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ESMO 2021
Trial
Phase 3, CheckMate649
Updated results from the CheckMate649 study report continued overall survival (OS) benefit of nivolumab/chemotherapy versus chemotherapy alone in patients with advanced gastric cancer (GC)/gastroesophageal junction cancer (GEJC)/oesophageal adenocarcinoma (EAC). In contrast, there was no OS benefit with nivolumab/ipilimumab versus chemotherapy. Recently, results from the randomised, global, phase 3 CheckMate649 study (NCT02872116) demonstrated superior OS with first-line nivolumab/chemotherapy versus chemotherapy in patients with advanced GC/GEJC/EAC, leading to FDA approval [1]. Dr Yelena Janjigian (Memorial Sloan Kettering Cancer Center, NY, USA) presented updated results from CheckMate649 with longer follow-up for nivolumab/chemotherapy versus chemotherapy and first results for nivolumab/ipilimumab versus chemotherapy [2]. In CheckMate649, 2,031 patients...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on